Edition:
United Kingdom

Denali Therapeutics Announces Positive Clinical Results With Its Lead RIPK1 Inhibitor Molecule


Monday, 19 Nov 2018 

Nov 19 (Reuters) - Denali Therapeutics Inc ::DENALI THERAPEUTICS ANNOUNCES POSITIVE CLINICAL RESULTS WITH ITS LEAD RIPK1 INHIBITOR MOLECULE AND INTENTION TO INITIATE PATIENT STUDIES IN MULTIPLE INDICATIONS IN COLLABORATION WITH SANOFI.DENALI THERAPEUTICS INC - DENALI AND PARTNER SANOFI PLAN TO EVALUATE DNL747 IN CLINICAL STUDIES FOR ALZHEIMER'S DISEASE.DENALI THERAPEUTICS INC - DENALI AND PARTNER SANOFI PLAN TO EVALUATE DNL747 IN CLINICAL STUDIES FOR ALS AND MULTIPLE SCLEROSIS (MS).DENALI THERAPEUTICS INC - PHASE 1 HEALTHY VOLUNTEER STUDY OF DNL747 MEETS ALL ENDPOINTS.DENALI THERAPEUTICS INC - IN ADDITION TO DNL747, SANOFI AND DENALI ARE PURSUING SEVERAL OTHER COMPOUNDS, INCLUDING DNL758.DENALI THERAPEUTICS INC - SANOFI INTENDS TO INITIATE CLINICAL TRIALS WITH DNL758 IN 2019.. 

Company Quote

25.17
-1.03 -3.93%
18 Apr 2019